Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle

Trial Profile

Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Ingenol disoxate (Primary)
  • Indications Actinic keratosis; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 13 Jun 2018 Status changed from active, no longer recruiting to discontinued.
    • 14 Apr 2018 This trial has been Discontinued in Germany.
    • 30 Mar 2018 This trial has been Discontinued in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top